Compounds > 1-(5-isoquinolinesulfonyl)-2-methylpiperazine

1-(5-isoquinolinesulfonyl)-2-methylpiperazine and glanatec

1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with glanatec in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Boland, S; Defert, O1
Colby, KA; Kinoshita, S; Kruse, FE1

Reviews

1 review(s) available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and glanatec

ArticleYear
Rho kinase inhibitors: a patent review (2014 - 2016).
    Expert opinion on therapeutic patents, 2017, Volume: 27, Issue:4

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Drug Design; Humans; Isoquinolines; Patents as Topic; Protein Kinase Inhibitors; rho-Associated Kinases; Sulfonamides

2017

Other Studies

1 other study(ies) available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and glanatec

ArticleYear
A Close Look at the Clinical Efficacy of Rho-Associated Protein Kinase Inhibitor Eye Drops for Fuchs Endothelial Corneal Dystrophy.
    Cornea, 2021, Oct-01, Volume: 40, Issue:10

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Ophthalmic; Benzoates; beta-Alanine; Clinical Trials as Topic; Fuchs' Endothelial Dystrophy; Humans; Isoquinolines; Ophthalmic Solutions; Protein Kinase Inhibitors; rho-Associated Kinases; Sulfonamides; Treatment Outcome

2021